Randomized phase 3 study of rituximab, cyclophosphamide, doxorubicin, and prednisone plus vincristine (R-CHOP) or bortezomib (VR-CAP) in newly diagnosed.
Forging a new standard in metastatic CRC
Is there Long-Term Benefit from Maintenance Rituximab?
